INmune Bio Inc
INMB
Get informed when a big investor buys or sells
+ FollowMarket Cap$61.68M
Close$
$0.83
66.1% downside
Current Fair Value
66.1% downsideOvervalued by 66.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $61.68 Million |
|---|---|
| Enterprise Value | $44.67 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.86 |
| Beta | 0.9 |
| Outstanding Shares | 26,718,507 |
Return
| Return on Equity | -90.44% |
|---|---|
| Return on Assets | -68.60% |
| Return on Invested Capital | 46.35% |
Valuation & Multiples
| P/E Ratio | -3.36 |
|---|---|
| PEG | 3.55 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 4.6 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$1.16 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7098▲ 1.24% |
|---|---|
| Total Calls | 44,100▼ 47.87% |
| Total Puts | 31,300▼ 46.95% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.23%▲ 1.10% |
|---|---|
| Total Invested | $6.09M▼ 23.28% |
| Investors Holding | 86▲ 9.00% |
ESG Score
No data